Radiochemioterapia adiuvante nei pazienti anziani affetti da glioblastoma: esperienza di un singolo istituto e revisione della letteratura

Translated title of the contribution: Adjuvant radiochemotherapy in the elderly affected by glioblastoma: Single-institution experience and literature review

A. Fiorentino, C. Chiumento, R. Caivano, M. Cozzolino, P. Pedicini, V. Fusco

Research output: Contribution to journalArticle

Abstract

Purpose: Radiochemotherapy (RCT) is the standard adjuvant treatment for patients affected by glioblastoma (GBM). As there is no evidence in elderly patients with GBM, combined, single modality or best supportive care is used. The aim of this retrospective study was to evaluate acute toxicity and outcome of elderly patients with GBM treated with RCT with temozolomide (TMZ). Materials and methods: Patients >65 years with newly diagnosed GBM who underwent surgery or biopsy and RCT were evaluated. Recursive Partitioning Analysis (RPA) class and National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 3 were used to classify patients and evaluate acute toxicity, respectively. Results: From April 2005 to January 2011, 35 patients (18 women and 17 men) with GBM were treated at our institution. Only 31.43% of cases underwent complete resection. Median progression-free survival (PFS) was 8 months and median overall survival (OS) 13 months. At univariate and multivariate analysis, only RPA class correlated with OS (p=0.01, p=0.03, respectively). During RCT, toxicity was mild (thrombocytopaenia G3-4, 11.43%; neurological toxicity, G3-4, 8.57%). Conclusions: Our data suggest that RCT with TMZ seems to produce a better outcome with a mild toxicity profile in elderly patients affected by GBM.

Original languageItalian
Pages (from-to)870-881
Number of pages12
JournalRadiologia Medica
Volume118
Issue number5
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Adjuvant Chemoradiotherapy
Glioblastoma
Chemoradiotherapy
temozolomide
Survival
National Cancer Institute (U.S.)
Disease-Free Survival
Multivariate Analysis
Retrospective Studies
Biopsy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Radiochemioterapia adiuvante nei pazienti anziani affetti da glioblastoma : esperienza di un singolo istituto e revisione della letteratura. / Fiorentino, A.; Chiumento, C.; Caivano, R.; Cozzolino, M.; Pedicini, P.; Fusco, V.

In: Radiologia Medica, Vol. 118, No. 5, 08.2013, p. 870-881.

Research output: Contribution to journalArticle

@article{043eab12cf5c47fc81624f7e5b013a11,
title = "Radiochemioterapia adiuvante nei pazienti anziani affetti da glioblastoma: esperienza di un singolo istituto e revisione della letteratura",
abstract = "Purpose: Radiochemotherapy (RCT) is the standard adjuvant treatment for patients affected by glioblastoma (GBM). As there is no evidence in elderly patients with GBM, combined, single modality or best supportive care is used. The aim of this retrospective study was to evaluate acute toxicity and outcome of elderly patients with GBM treated with RCT with temozolomide (TMZ). Materials and methods: Patients >65 years with newly diagnosed GBM who underwent surgery or biopsy and RCT were evaluated. Recursive Partitioning Analysis (RPA) class and National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 3 were used to classify patients and evaluate acute toxicity, respectively. Results: From April 2005 to January 2011, 35 patients (18 women and 17 men) with GBM were treated at our institution. Only 31.43{\%} of cases underwent complete resection. Median progression-free survival (PFS) was 8 months and median overall survival (OS) 13 months. At univariate and multivariate analysis, only RPA class correlated with OS (p=0.01, p=0.03, respectively). During RCT, toxicity was mild (thrombocytopaenia G3-4, 11.43{\%}; neurological toxicity, G3-4, 8.57{\%}). Conclusions: Our data suggest that RCT with TMZ seems to produce a better outcome with a mild toxicity profile in elderly patients affected by GBM.",
keywords = "Chemotherapy, Elderly, Glioblastoma, Radiotherapy",
author = "A. Fiorentino and C. Chiumento and R. Caivano and M. Cozzolino and P. Pedicini and V. Fusco",
year = "2013",
month = "8",
doi = "10.1007/s11547-012-0906-7",
language = "Italian",
volume = "118",
pages = "870--881",
journal = "Radiologia Medica",
issn = "0033-8362",
publisher = "Springer-Verlag Italia s.r.l.",
number = "5",

}

TY - JOUR

T1 - Radiochemioterapia adiuvante nei pazienti anziani affetti da glioblastoma

T2 - esperienza di un singolo istituto e revisione della letteratura

AU - Fiorentino, A.

AU - Chiumento, C.

AU - Caivano, R.

AU - Cozzolino, M.

AU - Pedicini, P.

AU - Fusco, V.

PY - 2013/8

Y1 - 2013/8

N2 - Purpose: Radiochemotherapy (RCT) is the standard adjuvant treatment for patients affected by glioblastoma (GBM). As there is no evidence in elderly patients with GBM, combined, single modality or best supportive care is used. The aim of this retrospective study was to evaluate acute toxicity and outcome of elderly patients with GBM treated with RCT with temozolomide (TMZ). Materials and methods: Patients >65 years with newly diagnosed GBM who underwent surgery or biopsy and RCT were evaluated. Recursive Partitioning Analysis (RPA) class and National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 3 were used to classify patients and evaluate acute toxicity, respectively. Results: From April 2005 to January 2011, 35 patients (18 women and 17 men) with GBM were treated at our institution. Only 31.43% of cases underwent complete resection. Median progression-free survival (PFS) was 8 months and median overall survival (OS) 13 months. At univariate and multivariate analysis, only RPA class correlated with OS (p=0.01, p=0.03, respectively). During RCT, toxicity was mild (thrombocytopaenia G3-4, 11.43%; neurological toxicity, G3-4, 8.57%). Conclusions: Our data suggest that RCT with TMZ seems to produce a better outcome with a mild toxicity profile in elderly patients affected by GBM.

AB - Purpose: Radiochemotherapy (RCT) is the standard adjuvant treatment for patients affected by glioblastoma (GBM). As there is no evidence in elderly patients with GBM, combined, single modality or best supportive care is used. The aim of this retrospective study was to evaluate acute toxicity and outcome of elderly patients with GBM treated with RCT with temozolomide (TMZ). Materials and methods: Patients >65 years with newly diagnosed GBM who underwent surgery or biopsy and RCT were evaluated. Recursive Partitioning Analysis (RPA) class and National Cancer Institute - Common Toxicity Criteria (NCI-CTC) version 3 were used to classify patients and evaluate acute toxicity, respectively. Results: From April 2005 to January 2011, 35 patients (18 women and 17 men) with GBM were treated at our institution. Only 31.43% of cases underwent complete resection. Median progression-free survival (PFS) was 8 months and median overall survival (OS) 13 months. At univariate and multivariate analysis, only RPA class correlated with OS (p=0.01, p=0.03, respectively). During RCT, toxicity was mild (thrombocytopaenia G3-4, 11.43%; neurological toxicity, G3-4, 8.57%). Conclusions: Our data suggest that RCT with TMZ seems to produce a better outcome with a mild toxicity profile in elderly patients affected by GBM.

KW - Chemotherapy

KW - Elderly

KW - Glioblastoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84884798553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884798553&partnerID=8YFLogxK

U2 - 10.1007/s11547-012-0906-7

DO - 10.1007/s11547-012-0906-7

M3 - Articolo

C2 - 23184248

AN - SCOPUS:84884798553

VL - 118

SP - 870

EP - 881

JO - Radiologia Medica

JF - Radiologia Medica

SN - 0033-8362

IS - 5

ER -